RNAZ Transcode Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1829635 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-435.7%
TTM EPS YoY81.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-866.1%
ROA-581.7%
ROIC (approx.)-909.8%
Asset turnover—
Leverage & solvency
Liabilities / assets28.2%
Debt / equity0.00x
Current ratio0.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-476.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $13.42M | $9.71M | $12.26M | $10.23M | $2.75M |
| SG&A expense | $5.77M | $5.95M | $7.15M | $8.40M | $3.40M |
| Operating income | -$27.98M | -$15.66M | -$19.42M | -$18.63M | -$6.15M |
| Interest expense | $6,616 | $26,813 | $55,899 | $31,986 | $95,070 |
| Pretax income | -$34.44M | -$16.75M | — | — | — |
| Income tax | $226,069 | $0 | $0 | $0 | $53,051 |
| Net income | -$34.66M | -$16.75M | -$18.55M | -$17.56M | -$6.84M |
| EBITDA | -$27.90M | -$15.57M | -$19.30M | -$18.54M | -$6.11M |
| EPS (basic) | -52.59 | -1,336.63 | -3,419.01 | -1,082.79 | -0.81 |
| EPS (diluted) | -52.59 | -1,336.63 | -3,419.01 | -1,082.79 | -0.81 |
| Weighted avg. shares (diluted) | 689,713 | 12,558 | 5,424 | 16,222 | 8.43M |
| Balance sheet | |||||
| Cash & equivalents | $17.81M | $5.81M | $2.77M | $4.97M | $20.83M |
| Current assets | $21.98M | $7.09M | $4.46M | $7.38M | $22.73M |
| PP&E, net | $370,681 | $51,574 | $120,707 | $208,581 | $206,268 |
| Goodwill | $25.74M | — | — | — | — |
| Intangibles | $114.30M | — | — | — | — |
| Total assets | $162.40M | $7.29M | $5.17M | $7.59M | $22.94M |
| Current liabilities | $3.49M | $2.77M | $3.49M | $4.35M | $2.53M |
| Total liabilities | $10.52M | $9.31M | $3.53M | $4.35M | $2.53M |
| Shareholders' equity | $10.34M | -$2.02M | $1.64M | $3.24M | $20.40M |
| Shares outstanding | 916,968 | 36,753 | 19,014 | 16,222 | 12.90M |
| Cash flow statement | |||||
| Operating cash flow | -$19.52M | -$13.34M | -$18.07M | -$15.76M | -$5.27M |
| Capital expenditure | $6,660 | $21,761 | $35,609 | $100,919 | $254,820 |
| Free cash flow | -$19.52M | -$13.36M | -$18.11M | -$15.86M | -$5.52M |
| Investing cash flow | -$4,436 | -$21,761 | -$35,609 | -$100,919 | -$251,820 |
| Financing cash flow | $31.52M | $16.40M | $15.91M | $5,989 | $25.52M |
| Depreciation & amortization | $76,446 | $90,894 | $123,483 | $98,606 | $42,470 |
| Stock-based compensation | $485,428 | $1.70M | $1.04M | $395,329 | $185,996 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.